• Profile
Close

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: An analysis of the BETonMACE randomized clinical trial

Cardiovascular Diabetology Jun 27, 2021

Schwartz GG, Nicholls SJ, Toth PP, et al. - Using data from the BETonMACE phase 3 trial, researchers sought to determine the correlation of insulin use with the risk of major adverse cardiovascular events (MACE) after acute coronary syndrome (ACS) in a contemporary cohort of patients receiving evidence-based background cardiovascular treatments, as well as to assess the interaction of insulin use and apabetalone, a bromodomain and extra-terminal protein inhibitor, on that risk. Eight hundred twenty-nine (34.2%) of the 2,418 patients who were followed for a median of 26.5 months were given insulin. Despite the use of evidence-based, contemporary therapies, insulin-treated patients with type 2 diabetes, low high-density lipoprotein cholesterol, and ACS are at high risk for recurrent MACE. After controlling for other risk factors for MACE, there is still a strong association between insulin treatment and the risk of MACE. There is an unmet need for more treatments to reduce this risk.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay